![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP
RNS Number : 6235B
GW Pharmaceuticals PLC
22 February 2011
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ----------------------------------------------- 1. Identity of the issuer or the GW Pharmaceuticals plc underlying issuer of existing shares to which voting rights are attached: -------------------------------------- ----------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------- An acquisition or disposal of voting rights X ----------------------------------------------------------------- ------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ----------------------------------------------------------------- ------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ----------------------------------------------------------------- ------ An event changing the breakdown of voting rights ----------------------------------------------------------------- ------ Other (please specify): ----------------- ---------------------------------------------- ------ 3. Full name of person(s) subject Great Point Partners LLC to the notification obligation: ------------------------------------ -------------------------------- 4. Full name of shareholder(s) (if Biomedical Value Fund, L.P. different from 3.): Biomedical Institutional Value Fund, L.P. Biomedical Offshore Value Fund Ltd. ------------------------------------ -------------------------------- 5. Date of the transaction and date January 7, 2011 on which the threshold is crossed or reached: ------------------------------------ -------------------------------- 6. Date on which issuer notified: February 17, 2011 ------------------------------------ -------------------------------- 7. Threshold(s) that is/are crossed Less than 5% or reached: ------------------------------------ -------------------------------- 8. Notified details: --------------------------------------------------------------------------------------------- A: Voting rights attached to shares --------------------------------------------------------------------------------------------- Class/type of shares if possible Situation previous using the to the triggering Resulting situation after the triggering ISIN CODE transaction transaction -------------- ---------------------- ----------------------------------------------------- Number Number of of Voting Number of Number of voting % of voting Shares Rights shares rights rights -------------- ---------- ---------- ---------- --------------------- ------------------ Direct Direct Indirect Direct Indirect -------------- ---------- ---------- ---------- ---------- --------- ------- --------- Ordinary shares 6,602,000 6,602,000 5,852,000 5,852,000 - 4.45% - ---------- ---------- ---------- ---------- --------- ------- --------- GB0030544687 -------------- ---------- ---------- ---------- ---------- --------- ------- --------- B: Qualifying Financial Instruments ------------------------------------------------------------------------------ Resulting situation after the triggering transaction ------------------------------------------------------------------------------ Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion rights that may rights Period be acquired if the instrument is exercised/ converted. ------------------ ----------- ------------ ----------------- ------------ C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ------------------------------------------------------------------------------- Resulting situation after the triggering transaction ------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of % of voting financial price date Conversion voting rights instrument period rights instrument refers to ----------- --------- ----------- ----------- ----------- ---------------- Nominal Delta ----------- --------- ----------- ----------- ----------- -------- ------ Total (A+B+C) ------------------------------------------------------ Number of voting rights Percentage of voting rights ------------------------ ---------------------------- 5,852,000 4.45% ------------------------ ---------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: --------------------------------------------------------------------------- Biomedical Value Fund, L.P 165 Mason Street 3(rd) Floor, Greenwich CT 06830 Biomedical Institutional Value Fund, L.P 165 Mason Street 3(rd) Floor, Greenwich CT 06830 Biomedical Offshore Value Fund, Ltd 165 Mason Street 3(rd) Floor, Greenwich CT 06830 Proxy Voting: ---------------------------------------- 10. Name of the proxy holder: - ------------------------------------ 11. Number of voting rights proxy - holder will cease to hold: ------------------------------------ 12. Date on which proxy holder will - cease to hold voting rights: ------------------------------------ 13. Additional information: ------------------------------------ -------------------------- Ron Panzier Chief Financial Officer 14. Contact name: Great Point Partners LLC ------------------------------------ -------------------------- 15. Contact telephone number: 001-203-971-3300 ------------------------------------ -------------------------- 16. Contact number at the Company: Adam George Company Secretary + 44 (0) 1980 557 000 ------------------------------------ --------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAPAAAAAFEEF
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions